NVAX

Novavax's stock price has shown significant volatility over the past six months, with a 22.78% increase over the past year and a 56.64% gain over the last six months, reaching $11.32 per share as of October 6, 2026. Key events include a major licensing and co-commercialization agreement with Sanofi in May 2024, which strategically repositioned Novavax as a leaner, partner-oriented vaccine platform company, providing immediate cash, future milestone potential, and access to Sanofi's commercial scale. For Q2 CY2026, reported on August 6, 2026, Novavax exceeded analyst expectations with revenues of $56.7 million, despite a 76.3% year-over-year decline, and reported a GAAP loss per share of -$0.32, which was better than consensus estimates. In October 2026, the stock experienced volatility, including a nearly 10% fall after a 20% gain, driven by concerns over a potential plague outbreak in Russia, underscoring investor sensitivity to infectious disease news.